Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bilastine + montelukast (Centaur Pharmaceuticals)
- Development stage
- Phase 4
- Lead developer
- Centaur Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Allerduo is a fixed-dose combination of the second-generation antihistamine bilastine and the leukotriene receptor antagonist montelukast. Developed by Centaur Pharmaceuticals, it is approved in India for the treatment of allergic rhinitis (hay fever) and comorbid asthma or allergic conditions. Bilastine acts as a selective antagonist of the histamine H1 receptor, preventing histamine-mediated symptoms such as sneezing, itching, and rhinorrhea. Montelukast selectively antagonizes the cysteinyl leukotriene receptor 1 (CysLT1), reducing leukotriene-mediated airway inflammation, mucus secretion, and bronchoconstriction. Together, these two active ingredients provide complementary, dual-pathway control of allergic symptoms with a favorable, non-sedating safety profile.
- Brand names
- Allerduo
- Other names
- Allerduo Oral SuspensionAllerduo Tabletbilastine and montelukastmontelukast + bilastine
02
Targets
CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)HRH1 (Histamine H1 Receptor)KCNH2 (Voltage-gated potassium channel subfamily H member 2)
Beyond the preview
Go deeper on bilastine + montelukast (Centaur Pharmaceuticals).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bilastine + montelukast (Centaur Pharmaceuticals).